UK government sets out position on future regulation of flea and tick medications

The government has yet to decide whether pet parasite treatments should be restricted to advice-based supply channels.
The UK Government responded to eight recommendations made by the House of Lords Environment and Climate Change Committee (ECCC) on pet parasite medications, published on 5 August.
The recommendations follow the Veterinary Medicines Directorate’s (VMD) April 2026 call for evidence on the environmental impact of pet parasite medications (PPMs), particularly those containing fipronil and imidacloprid – two commonly used ectoparasiticides in pets – and whether the supply categories of relevant products should change as a result.
GlobalPETS examines the recommendations with potential commercial implications for businesses, alongside the UK government’s position on each.
What businesses need to know
The government has agreed with three of the five recommendations identified as having potential commercial implications. The first recommendation calls on the VMD to publish anonymized data on pet parasite medication sales and usage, drawing on information from manufacturers, veterinary practices and Suitably Qualified Persons (SQPs).
The VMD already receives sales data for parasiticides through pharmacovigilance requirements, although this data primarily supports product safety monitoring and benefit-risk assessments.
It is also modernizing its digital systems to improve data collection and analysis, which could support the publication of aggregated and anonymized sales information where legally permissible and reasonably practicable.
However, sales figures alone cannot establish how products are used in practice, the government says. Additional behavioral, epidemiological and surveillance data is therefore necessary to assess usage patterns and potential environmental exposure.
Stricter product screening
The government has also agreed with the third recommendation, which calls for the VMD to introduce Phase II environmental risk assessments for existing and future pet parasite medications, citing insufficient pre-authorization and post-authorization processes.
Currently, environmental risk assessments for companion animal parasiticides stop at Phase I under international guidelines, based on the historical assumption that individual pet treatments pose negligible environmental exposure.
However, emerging evidence of contamination through wastewater and dogs swimming in surface waters has challenged this assumption.
Although the UK supports more comprehensive assessments, no agreed Phase II methodology currently exists for these products. The VMD has commissioned research into environmental exposure models, particularly those covering wastewater and surface-water pathways, to help develop future assessment methods and technical guidance.
The UK will continue working with international regulators toward a harmonized approach but may consider introducing Phase II assessments nationally if international agreement is delayed, once suitable scientific models have been established.
Improving consumer education
The UK has expressed its support for Recommendation 7, which calls for better training and advice for those supplying PPMs, enabling them to guide pet owners on individualized, risk-based treatment and ways to reduce environmental harm.
However, there is currently no agreed, evidence-based framework defining how risk-based use of ectoparasiticides should be applied in practice.
To address this gap, the VMD has commissioned research to establish the principles and risk factors that should inform treatment decisions. The findings are intended to support a consistent framework for veterinary professionals and SQPs advising pet owners.
The UK will continue working with SQPs, veterinary professionals and other relevant stakeholders to ensure that future training and guidance reflect the latest evidence and support the implementation of a clearly defined risk-based approach.
Product labeling
Businesses will not face changes to product labeling for now, as the government has rejected the recommendation to extend the period during which treated pets should not bathe or swim from four days to 28 days. The recommendation also calls for bathing restrictions to be clearly displayed on relevant product packaging rather than communicated solely through QR codes.
The government’s response cites insufficient evidence on the extent to which bathing and swimming contribute to the release of certain ectoparasiticides into the environment to justify extending these restrictions.
Any changes to product labeling should be supported by a robust environmental risk assessment framework, including validated exposure models and evidence of the effectiveness and proportionality of proposed measures.
Further research into risk-based use of ectoparasiticides is expected to inform future advice and potential additional measures. Until more evidence becomes available, the government considers existing guidance, supported by education and responsible-use initiatives, the most proportionate approach.
Pending decision
The UK has yet to make a decision on the recommendation to restrict access to pet parasite medications through advice-based supply channels.
This recommendation suggests ending the general sale of PPMs and requiring, at a minimum, that they be sold through Non-Food Animal – Veterinarian, Pharmacist, Suitably Qualified Person (NFA-VPS) channels, where an authorized professional can provide advice.
It argues that treatments should be based on each animal’s clinical needs, lifestyle, location and risk factors, rather than being routinely sold without evidence of need. It also calls for tighter controls on online sales to ensure products are not supplied without individualized advice.
The government recognizes concerns about routine PPM use but says any changes to distribution categories must balance environmental protection with animal welfare, public health, access to treatment, affordability and consumer choice.
The VMD is reviewing the distribution categories for products containing fipronil or imidacloprid. The review is supported by the April 2026 call for evidence, and a summary of responses was expected in late October 2026. A decision on whether all PPMs should be restricted to advice-based supply channels would be premature before the review is complete, the government says.
Other recommendations
The UK supports the recommendation to strengthen the evidence base on environmental contamination from pet parasite medications, including in waterways, soils and sewage sludge.
According to the government, work is already underway through the cross-government Pharmaceuticals in the Environment (PiE) group to improve understanding of the sources, pathways and impacts of veterinary medicines in the environment.
Relevant environmental agencies and regulators, including the Environment Agency (EA), the Scottish Environment Protection Agency and Natural Resources Wales, also work with other partners to monitor and assess environmental contamination in catchments.
The government has agreed with the recommendation to review governance arrangements between the VMD, industry and the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) to maintain regulatory independence and public confidence.
In response, the government reviewed the VMD’s decision-making processes, governance arrangements, funding model, engagement with industry and participation in international regulatory forums. It says appropriate safeguards, oversight mechanisms and transparency measures are in place, with no evidence of regulatory capture or undue influence.
Research funding
Lastly, the UK has expressed partial agreement with the recommendation to fund research addressing evidence gaps relating to parasite prevalence, zoonotic risks and the environmental and human health impacts of pet parasite medications.
The government noted that the VMD has already commissioned research to improve understanding of how ectoparasiticides are used in practice, the factors influencing parasite exposure and how risk-based treatment could be implemented.
However, it says the need for further research and surveillance will be assessed as evidence develops. The VMD will continue to consider relevant peer-reviewed studies and other robust published evidence when evaluating the risks and benefits of pet parasite medications.
Share this story:
One click prioritizes GlobalPETS in your search results and AI answers.
